NO-cGMP pathway drugs in aged animals: preclinical review of vascular function
A systematic review and meta-analysis of 13 preclinical studies in aged animals reports that agents targeting the NO-cGMP pathway improved measures of vascular function, with mixed risk of bias and heterogeneity. [1]
Automatic summary · not editorially reviewed
The key findings
The review included 13 preclinical studies in aged animal models of vascular dysfunction, covering DMARDs, PDE inhibitors and sGC modulators. [1]
DMARDs improved acetylcholine-induced vasorelaxation, while PDE inhibitors and sGC modulators improved microvascular perfusion. [1]
Risk of bias was mixed, with high risk in power reporting and some concerns about baseline comparability, allocation and incomplete outcome data. [1]
The source at a glance
- Study type / format
- Systematic review and meta-analysis of preclinical animal studies (abstract).
- Population / context
- Aged animal models of vascular dysfunction in preclinical studies.
- Summary based on
- Study abstract
- Original publication
- August 4, 2026
Aged animal models and NO-cGMP targets
The review addressed vascular dysfunction in aging, described as involving DNA damage, oxidative stress, chronic inflammation, mitochondrial dysfunction and cellular senescence, with endothelial impairment and reduced NO-cGMP signaling. The authors searched PubMed and Embase for preclinical studies of anti-inflammatory agents (DMARDs), phosphodiesterase (PDE) inhibitors and soluble guanylate cyclase (sGC) modulators in aged animal models of vascular dysfunction. Thirteen studies were included.
Supporting source [1]
Vasorelaxation and perfusion results by drug class
DMARDs (6 studies) improved acetylcholine-induced vasorelaxation (2.55 [1.68; 3.42]). PDE inhibitors improved sodium nitroprusside-induced vasorelaxation (0.5 [0.04; 0.96], 5 studies) and microvascular perfusion (0.76 [0.28; 1.25], 4 studies) but had no significant effect on acetylcholine-induced vasorelaxation. sGC modulators improved microvascular perfusion (1.12 [0.46; 1.78], 2 studies) without a significant effect on acetylcholine-induced vasorelaxation (0.45 [-0.23; 1.13], 3 studies). Pooled across all three classes, acetylcholine-induced vasorelaxation improved (1.73 [0.63; 2.82], 13 studies) and microvascular function improved with any NO-cGMP modulation (0.89 [0.49; 1.28], 6 studies).
Supporting source [1]
Mixed bias risk and cautious interpretation
Risk of bias was assessed with the SYRCLE tool plus reporting-quality items. Quality was mixed: risk was generally low for randomization except with PDE inhibitors, high for power reporting, and there were some concerns about baseline comparability, allocation and incomplete outcome data. The authors say the findings support multi-level targeting of vascular aging but should be interpreted cautiously given potential bias, heterogeneity and reliance on the quality of included studies.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The findings come from preclinical animal studies, not human outcome trials, and the authors caution about potential bias, heterogeneity and reliance on the quality of included studies.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Jouabadi SM, Golshiri K, Ataabadi EA, Boon Y, Kheiri F, Amiri A, Khajehali MH, Amiri A, Danser AHJ, Bramer WM, Roks AJM, Hooijmans CR. · europepmc.org · August 4, 2026